The Technology team advised Mercy BioAnalytics, Inc. on its $41 million Series A financing round.

The financing was led by Novalis LifeSciences, with participation from Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge, and Broadway Angels, an all-women venture capital group. The round also included strategic investments from Labcorp and Bruker, in addition to strong participation from existing investors.

Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer.

The Goodwin team was led by Bill Schnoor, Matt Reardon, Kristen McCarthyRich Matheny, Gozde Guckaya, Chris Denn, Alison Liou and Jim Matarese, with invaluable assistance from Khalid Elwanni.

For more details, read the press release.